You are great for game!

Faith lead a pioneering clinical trial for treatment of high-risk neuroblastoma.

Specifically, these researchers Accredited Group and Transnational Research on Cancer Clinic and the Pediatric Oncology Unit of Hospital Universitari La Fe attempt to evaluate the efficacy of two new drugs in pediatric cancers refractory to treatment,Researchers_and_artists_created_thes, or recur after initial treatment.

Children who will participate in the study, about 50, are children with disseminated disease (INSS stage 4, International Staging System for neuroblastoma: 40 to 50% of all neuroblastomas) or disease in INSS stage 2 or 3 with amplification of proto-oncogene N-myc (approximately 3% of all neuroblastomas).

Thus, it has been clearly see the association of this biological characteristic with an increased risk of relapse and death due to tumor progression. In fact, section chief of the Pediatric Oncology Unit of Hospital La Fe, Vitoria Castel, explained that these patients may benefit from more aggressive treatment, "with hopes of remission of their disease and based on this hypothesis, are included in this protocol. "

Treatment for high-risk neuroblastoma includes high-dose chemotherapy followed by surgery to remove as much tumor as possible, radiation therapy to the tumor site, megaterapia and hematopoietic stem cell transplantation, acid 13-cis-retinoic acid, and a clinical trial monoclonal antibody therapy, after chemotherapy.

For his part, Dr. Adela Canete has addressed in his presentation protocols for neuroblastoma treatment of low and intermediate risk. Similarly,The_claims_of_defaults_inp, the European study LINES, sponsored by the Health Research Institute of the Hospital La Fe for all of Europe, including all patients with neuroblastoma who are not high risk, their stratification into two groups based on their biology and clinical presentation .

The first, called low-risk, treatment aims to maintain a greater than 90% survival in all patients, decreasing the intensity of chemotherapy in those with neuroblastic tumors with no adverse biological features and keeping it in those whose characteristics are negative . The second group of intermediate risk, aims to confirm the results obtained by previous studies also maintaining higher survival rates to 80% with an adequate multidisciplinary treatment.

Treatment for relapses

By contrast, patients with neuroblastoma, which recurs after initial intensive treatment, have a high likelihood of disease progression. However, the European study evaluated TOTEM two new drugs that have shown a clear utility in initial studies and can be managed as outpatients, so that the patient has an excellent quality of life.

For its part, Silvestre Oltra Yania Yanez and has presented the advances in minimal residual disease (MRD) achieved by the group among which include the standardization of new methods for the detection of minimal residual disease, molecular and immunocytologically.

The Translational Research Group Cancer tackled from 12 years ago in neuroblastoma research projects geared to the study of micrometastases. These studies have focused on the detection of tumor cells in bone marrow samples, peripheral blood and apheresis for the auto transplant. During this period we have collected more than 2,300 samples from hospitals across Spain, serving as national focal point for these studies.

See more news here in Valencia.